Abstract:Fibroblasts are the major source of extracellular connective tissue matrix, and the recruitment and activation of these cells are thought to play an important role in wound healing and in the development of fibrosis. Agents that could block fibroblast accumulation could play a therapeutic role in modulating fibrosis. Previous studies have demonstrated that the phosphodiesterase 4 (PDE4) inhibitor SB207499 (Ariflo; Smith Kline Beecham; King of Prussia, PA) can attenuate fibroblast chemotaxis toward the chemoattractant fibronectin. Since the activity of a PDE4 inhibitor should be dependent on endogenous cyclic adenosine monophosphate levels, the current study was designed to determine if endogenous prostaglandin production rendered cells susceptible to the effects of Ariflo. To accomplish this, human fetal lung fibroblasts were cultured and, after achieving confluence, were incubated for 60 min with and without indomethacin (2 × 10−6 mol/L) to inhibit cyclooxygenase. Fibroblasts were then trypsinized and placed in the upper portion of a Boyden blindwell chemotaxis chamber. Fibronectin, 20 μg/mL, was placed in the lower portion of the chamber as the chemoattractant. Indomethacin (2 × 10−6 mol/L) was added to the upper side of the chemotaxis chamber. Indomethacin alone resulted in a slight but variable stimulation of chemotaxis (159 ± 33% compared to control p < 0.05). Ariflo added to control fibroblasts inhibited chemotaxis in a concentration-dependent manner. In three separate experiments, the concentration of Ariflo required to inhibit chemotaxis by 50% was 4.9 ± 2.5 μg/mL. In the presence of indomethacin, Ariflo inhibited chemotaxis only at the highest concentration tested, 10 μg/mL, reducing the response to 58.7 ± 21.0% of control (p < 0.005) compared to indomethacin. The current study, therefore, demonstrates that the PDE4 inhibitor Ariflo is dependent, at least in part, on endogenous cyclooxygenase activity and, presumably, prostaglandin production in order to exert its inhibitory effect on fibroblast chemotaxis. That Ariflo is active even in the presence of indomethacin suggests alternate mechanisms for stimulating cyclic adenosine monophosphate may also play a role. Since cyclooxygenase activity and prostaglandin production can be modulated by a variety of mediators present in an inflammatory milieu, fibroblasts in such a setting may be particularly sensitive to the inhibitory effects of Ariflo. Such an effect may have therapeutic potential in fibrotic disorders.

Cytokines Modulate Cilomilast Response In Lung Fibroblasts

Phosphodiesterase 4 Inhibitor Cilomilast Inhibits Fibroblast-Mediated Collagen Gel Degradation Induced by Tumor Necrosis Factor-Alpha and Neutrophil Elastase

PGE 2 Desensitizes Β -Agonist Effect on Human Lung Fibroblast-Mediated Collagen Gel Contraction Through Upregulating PDE4.

Cytokine Inhibition of Fibroblast-Induced Gel Contraction is Mediated by PGE(2) and NO Acting Through Separate Parallel Pathways.

PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels.

Th2 Cytokine Regulation of Type I Collagen Gel Contraction Mediated by Human Lung Mesenchymal Cells.

Activity of Matrix Metalloproteinase in Airway Epithelial Cells of COPD Patients.

Cilomilast Ameliorates Renal Tubulointerstitial Fibrosis by Inhibiting the TGF-β1-Smad2/3 Signaling Pathway

Interleukin-1α inhibits transforming growth factor-β1 and β2-induced extracellular matrix production, remodeling and signaling in human lung fibroblasts: Master regulator in lung mucosal repair

Synergetic Effect of Interleukin-4 and Transforming Growth Factor-Beta 1 on Type I Collagen Gel Contraction and Degradation by Hfl-1 Cells - Implication in Tissue Remodeling

Cilomilast Modulates Rhinovirus-Induced Airway Epithelial ICAM-1 Expression and IL-6, CXCL8 and CCL5 Production

Prostaglandin E(2) Mediates Il-1 Beta-Related Fibroblast Mitogenic Effects In Acute Lung Injury Through Differential Utilization Of Prostanoid Receptors

Inhibition of Pulmonary Fibrosis in Mice by Cxcl10 Requires Glycosaminoglycan Binding and Syndecan-4

The Role Of Fibulin-1C Peptides In Attachment, Proliferation And ECM Deposition In Lung Fibroblasts From Chronic Lung Diseases

Phosphodiesterase Inhibitor Attenuation of Fibroblast Chemotaxis Depends on Endogenous Prostaglandin Production

Chemokine (C‐X‐C motif) ligand 14 contributes to lipopolysaccharide‐induced fibrogenesis in mouse L929 fibroblasts via modulating PPM1A

Prostaglandin E₂ inhibits human lung fibroblast chemotaxis through disparate actions on different E-prostanoid receptors.

N-acetyl-l-cysteine Inhibits TGF-β1-induced Profibrotic Responses in Fibroblasts

PDE4 Inhibitors Roflumilast and Rolipram Augment PGE2 Inhibition of TGF-{beta}1-stimulated Fibroblasts.

Pro-Fibrotic Effects of CCL18 on Human Lung Fibroblasts Are Mediated via CCR6

Prostacyclin Analogs Inhibit Fibroblast Contraction of Collagen Gels Through the Camp-Pka Pathway